Dupilumab Maintains Its Effectiveness Up to Five Years in Patients With Eczema
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 12, 2024 -- For patients with atopic dermatitis (AD), dupilumab maintains its clinical effectiveness up to five years and is discontinued by 23.8 percent of patients, according to a study published online Aug. 7 in JAMA Dermatology.
Celeste M. Boesjes, M.D., from the University Medical Center Utrecht in the Netherlands, and colleagues examined clinical effectiveness and reasons for discontinuation of dupilumab treatment in 130 children, 1,025 adults, and 131 older adults with AD with up to five years of treatment.
The researchers found that most adults maintained controlled AD, with an Eczema Area and Severity Index (EASI) score of 7 or lower varying from 78.6 to 92.3 percent and a numeric rating scale (NRS) for pruritus of 4 or lower varying from 72.2 to 88.2 percent for up to five years of treatment; up to 70.5 percent of all patients extended the dosing interval to mostly 300 mg every three or four weeks. After five years of treatment, the mean EASI and NRS for pruritus were 2.7 and 3.5, respectively. After six months of treatment, median thymus- and activation-related chemokine levels decreased considerably, from 1,751 to 390 pg/mL, and remained low. The median eosinophil levels increased temporarily to week 16, then decreased significantly over time. After a median of 54.0 weeks, 23.8 percent of patients discontinued dupilumab, with adverse events and ineffectiveness being the most frequently reported reasons (7.6 and 6.6 percent, respectively).
"This study highlights the importance of multicenter registries to evaluate long-term treatment effects in large daily practice cohorts," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Sanofi and Regeneron, which manufacture dupilumab.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Novel Treatments Recommended for Management of Atopic Dermatitis in Adults
FRIDAY, July 25, 2025 -- In an update to the guidelines for managing atopic dermatitis in adults, four new treatment recommendations are presented. The focused update was...
High Dietary Inflammatory Index Tied to Increased Prevalence of Eczema
TUESDAY, July 15, 2025 -- A high dietary inflammatory index (DII), which quantifies the inflammatory potential of diet, is associated with increased prevalence of atopic...
Atopic Dermatitis May Be Linked to Increased Risk for CKD
TUESDAY, July 15, 2025 -- Atopic dermatitis (AD) was associated with an increased risk for chronic kidney disease (CKD) in an Asian population, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.